Top Story

ASH elects four executive committee members

October 18, 2014

ASH elected four new members to its executive committee, the organization’s governing body.

Kenneth C. Anderson, MD, will serve a 1-year term as vice president, followed by successive terms as president-elect and president. Anderson is director of the Lebow Institute for Myeloma Therapeutics and the Jerome Lipper Myeloma Center at Dana-Farber Cancer Institute. He also serves as Kraft family professor of medicine and vice chair of the Joint Program in Transfusion Medicine at Harvard Medical School.

figure In the Journals

Hydroxyurea, transfusions urged for sickle cell disease management

October 17, 2014
The use of hydroxyurea and transfusion therapy is “strongly recommended” for patients with sickle cell disease, according to an evidence-based report by an…
In the Journals

Modified gene therapy shows promise in SCID-X1

October 8, 2014
A majority of boys with X-linked severe combined immunodeficiency experienced T-cell recovery and infection clearance after undergoing gene therapy with a…
In the Journals

Eclampsia, acute systemic infection increased risk for postpartum VTE

October 8, 2014
Women with preeclampsia/eclampsia and postpartum acute systemic infection experienced the greatest risk for developing venous thromboembolism during the first 3 weeks…
CME CNE
figure

Treatment Decision-Making through the Spectrum of MDS: Case 2 High Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »
CME
figure

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates - Monograph

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »

Filter By:

figure Institution Notes

ASH elects four executive committee members

October 18, 2014
ASH elected four new members to its executive committee, the organization’s governing body.Kenneth C. Anderson, MD, will serve a 1-year term as…
figure In the Journals

Hydroxyurea, transfusions urged for sickle cell disease management

October 17, 2014
The use of hydroxyurea and transfusion therapy is “strongly recommended” for patients with sickle cell disease, according to an…
In the Journals

Modified gene therapy shows promise in SCID-X1

October 8, 2014
A majority of boys with X-linked severe combined immunodeficiency experienced T-cell recovery and infection clearance after undergoing gene therapy…
In the Journals

Eclampsia, acute systemic infection increased risk for postpartum VTE

October 8, 2014
Women with preeclampsia/eclampsia and postpartum acute systemic infection experienced the greatest risk for developing venous thromboembolism during…
In the Journals

Somatic mutations linked to malignant transformation of aplastic anemia

October 6, 2014
Somatic mutations in patients with aplastic anemia were associated with longer disease duration and an increased risk for transformation to…
FDA News

FDA grants fast track designation to NKTT120 for sickle cell disease

October 2, 2014
The FDA granted fast track designation to NKTT120 as a potential treatment for patients with sickle cell disease, the drug’s manufacturer…
In the Journals

Target-specific oral anticoagulants reduced risk for bleeding in VTE, atrial fibrillation

September 30, 2014
Target-specific oral anticoagulants reduced the risk for major, fatal and intracranial bleeding compared with vitamin K antagonists in patients with…
figure Meeting News Coverage Perspective

SECURITY: 6-month DAPT performed similar to 12 months with DES implantation

September 30, 2014
WASHINGTON — The use of a 6-month vs. 12-month regimen of dual antiplatelet therapy yielded comparable outcomes after the implantation of a…
Meeting News Coverage

Rivaroxaban reduced VTE recurrence, major bleeding in patients with cancer

September 28, 2014
Rivaroxaban demonstrated comparable efficacy and a better safety profile compared with standard therapy in patients with venous thromboembolism and…
figure Meeting News Coverage Perspective

BRIGHT: Bivalirudin outperformed heparin alone, heparin plus tirofiban in PCI

September 26, 2014
WASHINGTON — Bivalirudin was superior to both heparin alone and heparin plus tirofiban in patients with acute MI undergoing coronary…
More Headlines »